ALK-Abello A/S/ DK0061802139 /
2024-03-25 12:10:00 PM | Chg. - | Volume | Bid9:00:01 AM | Ask9:00:01 AM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
125.60DKK | - | 1 Turnover: 125.60 |
-Bid Size: - | -Ask Size: - | 28.11 bill.DKK | - | 83.88 |
GlobeNewswire
2022-03-03
Clinical trial waiver in China opens door to 2022 registration filing for ALK’s dust mite allergy ta...
GlobeNewswire
2022-02-08
Annual report 2021: ALK delivers strong sales growth of 12% with tablet sales up 29% and EBITDA up 3...
GlobeNewswire
2021-08-04
Otonomy Reports Second Quarter 2021 Financial Results and Provides Corporate Update
GlobeNewswire
2021-07-30
ALK and Grandpharma team up to market the first adrenaline autoinjector in China
GlobeNewswire
2021-05-11
Otonomy Reports First Quarter 2021 Financial Results and Provides Corporate Update
GlobeNewswire
2021-02-11
Otonomy Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
GlobeNewswire
2020-08-04
Otonomy Reports Second Quarter 2020 Financial Results and Provides Corporate Update